Targeted Oncology Launches its Latest Virtual Tumor Board on Multiple Myeloma

Article

<em>Targeted Oncology</em>&trade; will launch its third &ldquo;Expert Perspective: Virtual Tumor Board&rdquo; on Monday, September 24.&nbsp;Each Virtual Tumor Board is a video-editorial discussion that features key opinion leaders from a specific oncological field considering options for treating patients based on case scenarios. This episode will focus on multiple myeloma.

Targeted Oncology&trade;, a print and digital resource that offers content and expert opinions on standard and emerging treatments in the oncology field, will launch its third &ldquo;Expert Perspective: Virtual Tumor Board&rdquo; on Monday, September 24. Each Virtual Tumor Board is a video-editorial discussion that features key opinion leaders from a specific oncological field considering options for treating patients based on case scenarios. This episode will focus on multiple myeloma.

&ldquo;We look forward to launching the next Virtual Tumor Board on September 24,&rdquo; said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company ofTargeted Oncology. &ldquo;Expert leaders will really get the chance to dive in to several patient&rsquo;s cases and truly help make a difference in the multiple myeloma community.&rdquo;

The Virtual Tumor Board will feature experts providing in-depth analysis on four patients with multiple myeloma and sharing information on their diagnoses, pathology results and treatment strategies from a collaborative medical setting based on recent data and clinical trial findings. With these cases, the multidisciplinary team discuss high-risk cytogenetics, maintenance therapy, the possibility for CAR T-cell therapy, and more for specific instances of multiple myeloma.

The key opinion leaders participating in this Virtual Tumor Board are:

  • Ajai Chari, M.D., associate professor, department of medicine, hematology and medical oncology, Mount Sinai Hospital
  • C. Ola Landgren, M.D., Ph.D., board-certified hematologic-oncologist, Memorial Sloan Kettering Cancer Center
  • Pei Lin, M.D., professor and section chief, myeloma, The University of Texas MD, Anderson Cancer Center
  • Nina Shah, M.D., associate professor, hematologist-oncologist, University of California San Francisco

About Targeted Oncology&trade;

Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Related Content